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measurements like waist circumference (WC) may deﬁne obesity
and explain its health consequences. The objective of this study
was to determine if utility (EQ5Dindex) varied by BMI category,
as WC varied. METHODS: This retrospective study used the
latest data from the England Health Survey (2003). A general
linear model (GLM) was developed that included factors associ-
ated with utility, standardising for age and sex to generate esti-
mates of utility with relation to obesity (obesity categories:
normal [Nl, BMI 18.5–24.9kg/m2], overweight [Ov, 25.0–29.9
kg/m2], obese [Ob, ≥30kg/m2], and thirties of WC, L = low, M
= medium, and H = high). RESULTS: The standardised mean
utility by BMI category for men was: Nl = 0.877, Ov = 0.894,
Ob = 0.858. Standardised mean utility by BMI category for
women was: Nl = 0.879, Ov = 0.871, Ob = 0.812. Standardised
mean utility by WC category for men was: L = 0.887, M = 0.877,
H = 0.866. Standardised mean utility by WC category for women
was: L = 0.872, M = 0.857, H = 0.833. BMI and WC were depen-
dent and interacting determinants of utility. For females in the
nine obesity groups, the standardised mean utility was as
follows: Nl/L = 0.878, Nl/M = 0.877, Nl/H = 0.882, Ov/L =
0.896, Ov/M = 0.873, Ov/H = 0.844, Ob/L = 0.842, Ob/M =
0.822, Ob/H = 0.774. For men: Nl/L = 0.862, Nl/M = 0.882,
Nl/H = 0.888, Ov/L = 0.907, Ov/M = 0.893, Ov/H = 0.883,
Ob/L = 0.892, Ob/M = 0.856, Ob/H = 0.828. CONCLUSIONS:
In both women and men, the highest EQ5Dindex values (best QoL)
was evident in overweight people with a low WC. A reduction
in WC in obese people resulted in a greater gain in utility than
the same change in normal or overweight people. Use of both
BMI and WC, rather than a single measure of obesity, provided
a more precise prediction of health-related utility. Utility varied
more widely as a function of waist circumference in higher BMI
categories.
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Based on 31 concept-elicitation interviews of former smokers
and individuals who wanted to lose weight, a questionnaire was
developed simultaneously in three languages (French, US-English
and US-Spanish). Draft items were generated in each language
and culturally adapted into Spain-Spanish and UK-English. Face
validity was assessed through 30 cognitive debrieﬁng interviews;
resulting in a 27-item questionnaire. OBJECTIVE: To validate a
questionnaire that investigates the positive well-being associated
with behavioral changes in adults. METHODS: The psychome-
tric properties of the questionnaire were examined in US-English,
US-Spanish and French through a stand-alone study in former
smokers and individuals who wanted to lose weight. RESULTS:
Based on an initial Principal Component Analysis (PCA) and
item-item correlation analysis, 18 items were retained. A ﬁnal
PCA indicated that the questionnaire encompassed ﬁve dimen-
sions: Serenity; Healthy Lifestyle, Support from Others, Self-
Conﬁdence, and Social Life. The questionnaire surpassed the
threshold for internal consistency reliability for all dimensions
and globally (Cronbach’s alpha > 0.8) in both behavioral changes
and in all languages. All items surpassed the criterion for item-
convergent validity and item-discriminant validity was satisfac-
tory for 17/18 items. Correlations between the questionnaire and
the Psychological General Well-Being index (PGWBi) scores con-
ﬁrmed its validity and indicated that it supplements information
obtained through the PGWBi. Known-groups validity was satis-
factory in individuals who wanted to lose weight based on the
amount of weight lost, BMI reduction and number of weight loss
attempts, but was inconclusive in former smokers because the
abstinence status and the discontinuation of smoking cessation
aids were not conﬁrmed. CONCLUSION: Results support the
reliability and validity of this questionnaire making it a useful
tool for determining the positive well-being associated with
behavioral changes. The questionnaire is currently undergoing
additional validity testing in a population where smoking status
is assessed.
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OBJECTIVE: To analyze morbidity, mortality and the impact on
cost-effectiveness caused by the delay in having adequate arteri-
ovenous ﬁstulae (AVF) at start of periodic hemodialysis (PHD).
METHODS: Prospective study of 110 patients who started PHD
between January 1st 2002 and July 31 2004 with creatinine
clearance of 5–10mL/minute/1,73m_. Data: sociodemographic,
Charlson Comorbidity Index (CCI), type and duration of the
vascular access (VA), “de novo” morbidity and hospitalisations.
Patients were separated into three groups according to the VA at
start PHD (AVFgroup): Group 1(G1) having an adequate func-
tioning AVF before initiating HD; group 2(G2) not having an
AVF at the start of HD, but having it before three months; group
3(G3) using catheters during the ﬁrst three months. Patients who
had a delayed nephrology referral, those who suddenly started
PHD and those with Diabetes mellitus were excluded because
these are mortality risk factors. RESULTS: There were no sig-
niﬁcant differences between the three groups with respect to
initial variables of patients: age (p = 0.10), sex (p = 0.45), diag-
nostic of renal disease (p = 0.24) and CCI (p = 0.76). G1 patients
had lower “de novo” morbidity and less hospitalisations (p =
0.000). A logistic regression was applied with morbidity and hos-
pitalisations as dependent variables and age, sex, CCI and AVF-
group as co-variables: G2 and G3 were independently associated
with higher morbidity and hospitalisations (p < 0.01). Kaplan-
Meier analysis showed that G1 had better survival than G2 and
G3 (33 months vs. 27 and 24); and patients without morbidity
had better survival than those with. The Cox Regression (time
dependent model) analysis showed that not having an adequate
AVF at start of PHD (G2 and G3) reduced survival (RR:11.32;
CI:1.06–120.6). Cost-effectiveness analysis showed that G1
patients with respect to G2 and G3 had better survival and lower
cost per live gained month. CONCLUSIONS: “De novo” mor-
bidity caused by not having an adequate AVF at start of PHD
considerably decreases survival and implies higher cost.
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